Study Warns of Kidney Damage Risk with Popular Mesothelioma Drug, Reports Surviving Mesothelioma
Researchers say pemetrexed (Alimta), the top chemotherapy drug for mesothelioma, may carry a risk of acute kidney injury, even in patients whose baseline kidney function falls within recommended limits.
Raleigh, NC (PRWEB) July 16, 2014
Italian scientists say patients on the popular mesothelioma drug pemetrexed may need to take certain precautions to avoid damaging their kidneys. An article on the new research has just been published on the Surviving Mesothelioma website. Click here to read it now.
Kidney specialists at St. Andrea Hospital in La Spezia analyzed the treatment records of 38 patients with non-small cell lung cancer who developed acute kidney injuries after treatment with pemetrexed. The problems occurred in 21% of patients, even though their baseline kidney function tests (eGFR) met the recommended levels for pemetrexed treatment.
“There is no clear cut eGFR above which pemetrexed may be used without potential risks of renal toxicity. If pemetrexed has to be used, all the coexisting risk factors for AKI should be possibly corrected,” concludes lead investigator, Giuseppe Rombola.
Pemetrexed, along with surgery and/or radiation, is a leading treatment for malignant mesothelioma, an asbestos-linked cancer with no known cure.
“This news is potentially significant for mesothelioma patients because so many of them are on or will be on pemetrexed,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “It sends a message that the potential for kidney damage should not be ignored, even among patients who do not appear to be at high risk.”
To read the details of the new study and its possible implications for mesothelioma patients, see Kidney Risk May be Unavoidable with Top Mesothelioma Drug, now available on the Surviving Mesothelioma website.
Rombola, G, et al, “Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage”, June 23, 2014, Journal of Nephrology, http://link.springer.com/article/10.1007/s40620-014-0117-5#page-2
For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/07/prweb12014002.htm